{"filings":[{"id":1093916,"accession_number":"0001104659-26-074915","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-06-17T12:52:16+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).","9 patients remain on treatment; median follow-up 9.8 months; no new safety signals.","First patient dosed in TARGET-D 201 Phase 2 registration trial of VS-7375 (KRAS G12D) in second-line mPDAC.","PanCAN provided $3.8M Therapeutic Accelerator Award in 2022 for RAMP 205 research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649919,"accession_number":"0001104659-26-066026","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-05-26T12:15:11+00:00","items":["5.07"],"status":"ready","headline":"Verastem shareholders elect three Class II directors, approve equity plans at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Bailey, Brian Stuglik, Karin Tollefson elected Class II directors; each received over 51M votes for.","Amended 2021 Equity Incentive Plan approved: 49.8M votes for, 4.5M against, 14.2M broker non-votes.","Amended 2018 Employee Stock Purchase Plan approved: 53.6M for, 0.8M against, 14.2M broker non-votes.","Ratification of Ernst & Young LLP as auditor: 67.7M for, 0.4M against, 1.3M abstain.","Non-binding advisory vote on executive compensation approved: 51.7M for, 2.5M against, 14.2M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93418,"accession_number":"0001104659-26-057126","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem posts updated corporate presentation on RAS/MAPK pipeline; no new financial data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation dated May 7, 2026, furnished as Exhibit 99.1.","Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.","No specific financial results, guidance, or material developments disclosed.","Presentation available on company website for investor reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105016,"accession_number":"0001104659-26-023462","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem posts updated corporate presentation; no specific financial or clinical data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.","Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.","No revenue, trial results, or other material metrics provided in the 8-K or the exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105015,"accession_number":"0001104659-26-010036","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Verastem reports preliminary 2025 product revenue $30.9M; cash runway to H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary AVMAPKI FAKZYNJA CO-PACK net revenue: Q4 2025 ~$17.5M, full year 2025 ~$30.9M (launch from May 2025).","Cash, equivalents, investments $205M at Dec 31, 2025; pro-forma $234M netting $29.4M from warrant exercises.","Anticipates LGSOC commercial launch and development to be self-sustaining by 2H 2026.","VS-7375 KRAS G12D inhibitor: interim Phase 1/2 update in 1H 2026; FDA discussions on registration-directed trials planned.","RAMP 205 PDAC expansion cohort update with ≥6 months follow-up expected in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":30914000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105014,"accession_number":"0001104659-26-002135","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.","Phase 3 RAMP 301 trial fully accrued; topline PFS data expected mid-2027.","VS-7375 KRAS G12D inhibitor: cleared 900 mg QD dose no DLTs; FDA FTD in PDAC.","Pipeline milestones: RAMP 205 update 1H2026; VS-7375 monotherapy expansion cohorts 1H2026.","Extended cash runway into 1H2027 via Oberland debt refinancing and equity investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121258,"accession_number":"0001104659-25-125309","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).","As of Nov 26, 2025: doublet in G12C-naive patients achieved ORR 40% (12/30), mPFS 11.1 months.","Previously G12C-treated patients in doublet: ORR 9.5% (2/21), mPFS 3.7 months.","Triplet combo: ORR 50% (2/4) in naive; 36% (4/11) tumor reduction in pretreated.","VS-7375 showed 69% ORR (11/16) in KRAS G12D NSCLC; no DLTs observed across RAMP 203."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121257,"accession_number":"0001104659-25-123295","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.","Matthew Ros, COO, departs; receives nine-month base salary continuation and pro-rated bonus under separation agreement.","RAMP 301 Phase 3 trial in recurrent LGSOC completed additional enrollment of 29 patients; topline data expected mid-2027.","Commercial launch of AVMAPKI FAKZYNJA CO-PACK progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121256,"accession_number":"0001104659-25-112946","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Verastem raises ~$96.9M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 8,543,794 firm shares and 3,870,000 pre-funded warrants at $7.25/share; underwriters exercised full option for 1,862,069 additional shares.","Net proceeds estimated at ~$96.9M after underwriting discounts and expenses.","Pre-funded warrants have $0.0001 exercise price, no expiration, and include 4.99% beneficial ownership limitation.","Closing expected on or about November 17, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121255,"accession_number":"0001104659-25-105923","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.","GAAP net loss $98.5M ($1.35/share) vs $24.0M ($0.60) YoY; non-GAAP adjusted net loss $39.4M ($0.54/share).","Cash $137.7M; with product revenue and warrant exercises, runway into H2 2026.","VS-7375 cleared 400 mg and 600 mg QD monotherapy with no DLTs; no nausea/vomiting/diarrhea >Grade 1.","RAMP 301 (LGSOC) completed targeted enrollment of 270 patients early; IDMC recommended 29 additional patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":13379000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121254,"accession_number":"0001104659-25-101817","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.","4 of 5 efficacy-evaluable patients had tumor reduction and remain on treatment.","Enrollment started for VS-7375 + cetuximab combo cohort in advanced solid tumors.","Interim safety/efficacy update expected in first half 2026.","Monotherapy dose escalation continues to 900 mg QD to select recommended Phase 2 dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121253,"accession_number":"0001104659-25-100537","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.","Month-four OS rate 92.2%, median OS not reached; median PFS 5.52 months, 4-month PFS rate 78.2%.","91.5% of patients had tumor reduction; 47% still on treatment; longest treatment >1 year.","Safety: 30.3% Grade 3 TRAEs, 3% discontinuation due to TRAEs, no TRAE-related deaths; mean dose intensity 93%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137905,"accession_number":"0001104659-25-088021","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.","RAMP 201 trial showed 44% ORR and median DoR 3.3-31.1 months for approved combination.","RAMP 205 dose level 1 in 1L metastatic pancreatic cancer achieved 83% confirmed ORR (10/12).","VS-7375 (KRAS G12D inhibitor) Phase 1/2a trial dosed first patient in U.S.; Fast Track designation granted.","RAMP 301 confirmatory trial enrollment on track for completion by end of 2025; IDMC recommendation expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137904,"accession_number":"0001104659-25-077659","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.","Across all dose levels, ORR 57.7% (15/26) and DCR 88.5% (23/26) in evaluable advanced NSCLC patients.","Safety profile: TRAEs in 27.5% (39/142), Grade≥3 SAEs in 7.7% (11/142); no TRAE-related deaths; 6 discontinuations.","Data to be presented in mini oral at IASLC WCLC on Sept 7, 2025; builds on prior ASCO ORR of 42% (n=12)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155297,"accession_number":"0001104659-25-055322","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.","RAMP 205 Phase 1/2 in first-line mPDAC: 83% unconfirmed ORR (10/12) at dose level 1; all patients had tumor shrinkage.","RP2D set: avutometinib 2.4mg, defactinib 200mg, gemcitabine 800mg/m2, nab-paclitaxel 125mg/m2.","VS-7375: oral KRAS G12D ON/OFF inhibitor with potent preclinical selectivity and activity; Phase 1/2a trial planned.","Preliminary data suggest patients may exceed historical median PFS for gemcitabine/nab-paclitaxel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155296,"accession_number":"0001104659-25-055286","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.","No dose-limiting toxicities observed across 100-900 mg QD; TRAEs mostly Grade 1/2; no TRAE-related deaths.","U.S. Phase 1/2a study for VS-7375 to start at 400 mg dose; plans to evaluate monotherapy and combinations in pancreatic, colorectal, and NSCLC.","Data presented at ASCO 2025; GenFleet is partner in China; Verastem holds rights in U.S. and other regions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155295,"accession_number":"0001104659-25-052220","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.","Across all 5 dose cohorts, 92% (48/52) of evaluable patients showed tumor reduction.","Company plans to start registrational Phase 3 trial in front-line metastatic PDAC in 2026.","No new safety signals; adverse events consistent with previously reported profile.","R&D webcast on June 2, 2025 to discuss RAMP 205 data and VS-7375 KRAS G12D inhibitor data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155294,"accession_number":"0001104659-25-046175","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Verastem's AVMAPKI FAKZYNJA for KRAS-mutated recurrent LGSOC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First-ever FDA-approved treatment for KRAS-mutated recurrent LGSOC; accelerated approval based on Phase 2 RAMP 201.","RAMP 201 showed 44% overall response rate (BIRC) in 57 patients; median duration of response range 3.3–31.1 months.","Approval granted May 8, 2025, ahead of the June 30 PDUFA date; continued approval contingent on confirmatory trial.","AVMAPKI FAKZYNJA CO-PACK expected to be commercially available in the U.S. within one week.","Verastem to host investor call at 2:30 pm ET today to discuss the approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155293,"accession_number":"0001104659-25-039098","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Verastem raises $75M private placement for ovarian cancer drug launch and R&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.","Placement led by RTW Investments; includes BVF, Nantahala, Octagon, OrbiMed, Stonepine.","Net proceeds to fund potential launch of avutometinib/defactinib in LGSOC, R&D for VS-7375, and working capital.","Pre-funded warrants exercisable at $0.0001/share, no expiration; closing expected April 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173812,"accession_number":"0001104659-25-026130","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.","RAMP 201 data: 44% ORR in KRAS mt, 31% overall; median PFS 12.9 months; 82% of patients had tumor shrinkage.","Confirmatory RAMP 301 Phase 3 enrollment on track for completion by end of 2025.","Filed U.S. IND for VS-7375 (KRAS G12D inhibitor) in Q1 2025; Phase 1/2a initiation expected mid-2025.","Plan to present RAMP 203 (NSCLC) and RAMP 205 (pancreatic) data at med meetings in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173811,"accession_number":"0001104659-25-005460","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.","Rights cover worldwide development and commercialization outside mainland China, Hong Kong, Macau, and Taiwan.","Updated corporate presentation posted Jan 23, 2025; no specific financial or pipeline data disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173810,"accession_number":"0001104659-25-004918","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Verastem appoints Matthew E. Ros as COO effective Jan 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew E. Ros appointed Chief Operating Officer; reports to CEO Daniel W. Paterson.","Initial annual base salary of $485,000 and target bonus of 45% of base salary.","Receives 50,000 time-based RSUs vesting over 4 years and 33,333 milestone-based RSUs.","Severance: 9 months salary and COBRA if terminated without cause or for good reason.","Change-of-control triggers accelerated vesting of time-based awards and 12 months salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173809,"accession_number":"0001104659-25-002859","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.","Pro forma cash $128.6M including $7.5M equity placement (1.4M shares at $5.2931/share).","FDA accepted NDA for avutometinib+defactinib in KRAS mutant LGSOC; PDUFA June 30, 2025; no AdCom planned.","Revenue participation: Oberland gets 1% of first $100M annual net sales (max 2% if full $150M drawn).","Strategic collaboration with IQVIA to support potential launch mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190790,"accession_number":"0001104659-24-109439","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.","Median duration of response 31.1 months; median PFS 12.9 months overall.","Discontinuation rate due to AEs was 10%; safety manageable with dose modifications.","Low-dose regimen (1.6 mg avutometinib) suboptimal; 22% progressed within 4 months vs 12% at 3.2 mg.","Rolling NDA submission to FDA for avutometinib+defactinib in recurrent LGSOC is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207264,"accession_number":"0001104659-24-082526","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Verastem raises ~$51.1M in underwritten offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["13.3M shares of common stock and 13.3M warrants offered at $3.00 per combined unit.","An additional 5M pre-funded warrants with warrants offered at $2.999 per unit.","Net proceeds expected to be ~$51.1M after underwriting discounts and expenses.","Closing expected on or about July 25, 2024; warrants expire 18 months from issuance.","Warrant exercise price is $3.50 per share; pre-funded warrants exercisable at $0.001 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207263,"accession_number":"0001104659-24-081882","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Verastem initiates rolling NDA for avutometinib/defactinib; RAMP 201 median duration 9 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rolling NDA for avutometinib+defactinib in recurrent KRAS mutant LGSOC started May 2024; priority review requested.","RAMP 201 interim data (Feb 2024 cutoff): median duration 9 months; KRAS mt 14 months, KRAS wt 7 months; 31/58 KRAS mt still on treatment.","Estimated addressable market: annual ~$300M KRAS mt, ~$270M KRAS wt; prevalent ~$1.7B KRAS mt, ~$1.1B KRAS wt based on $34k/month cost.","GenFleet collaboration: IND cleared June 2024, first patient dosed in China Phase 1/2 for KRAS G12D inhibitor GFH375/VS-7375."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224663,"accession_number":"0001104659-24-074956","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem initiates rolling NDA for avutometinib+defactinib in recurrent LGSOC; ORR 27%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rolling NDA submission for avutometinib + defactinib in recurrent LGSOC started H2 2024; potential FDA approval in 2025.","RAMP 201 trial (Feb 2024 cutoff): ORR 27% overall (95% CI 19%-36%), 37% KRAS mt, 15% KRAS wt.","Clinical benefit rate (CR+PR+SD≥6 months) 60%; discontinuation due to AEs only 9%.","No FDA-approved treatments for LGSOC; SoC studies show ORR 6-13% with 17-30% discontinuation.","Market opportunity: $1.7B+ prevalent KRAS mt addressable; 70% of oncologists surveyed would adopt within 6 months of approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224662,"accession_number":"0001104659-24-064919","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verastem initiates rolling NDA to FDA for avutometinib/defactinib in KRAS mutant LGSOC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Rolling submission of NDA seeking accelerated approval for recurrent KRAS mt LGSOC; initial sections include nonclinical and quality.","Clinical module to be submitted in H2 2024 with mature RAMP 201 data including 12-month follow-up; priority review to be requested.","As of Feb 2024 data cutoff: confirmed ORR by BICR 27% overall, 37% (KRAS mt, n=57) and 15% (KRAS wt, n=52); 60% clinical benefit rate ≥6 months.","Discontinuation due to AEs was 9%; median duration of therapy in Part A: 11 months overall, 18 months KRAS mt, 8 months KRAS wt.","No FDA-approved treatments exist for recurrent LGSOC; company plans focused commercial launch targeting top 400 HCPs with 14-18 reps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224661,"accession_number":"0001104659-24-064781","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Verastem reports 83% confirmed ORR in RAMP 205 dose level 1 for first-line metastatic pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.","41 patients enrolled across 4 dose/schedule cohorts of avutometinib+defactinib+gemcitabine+nab-paclitaxel.","21 of 26 evaluable patients had reduction in target lesion sum of diameters as of May 14, 2024 cutoff.","12 patients experienced SAEs (11 grade ≥3); 2 discontinued due to treatment-emergent AEs.","Investor call on May 24, 2024 to discuss these data and rolling NDA submission in recurrent KRAS mutant LGSOC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224660,"accession_number":"0001104659-24-045266","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem outlines NDA filing plan for avutometinib/defactinib in LGSOC by H1 2024; cash $137.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline data from RAMP 201 trial of avutometinib + defactinib in LGSOC expected H1 2024; rolling NDA for accelerated approval to commence same period.","Confirmed ORR of 45% with tumor shrinkage in 86% of evaluable patients from RAMP 201 Part A (June 2023 data).","GenFleet partnership: IND for oral KRAS G12D inhibitor GFH375/VS-7375 expected in China H1 2024; Phase 1 initiation H2 2024.","Initial safety/efficacy data from RAMP 205 (avutometinib + gemcitabine/nab-paclitaxel + defactinib) in front-line metastatic pancreatic cancer due H1 2024.","Ended Q4 2023 with $137.1M cash; GAAP operating expenses $31.14M ($29.54M non-GAAP) in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243938,"accession_number":"0001104659-24-007712","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.","Initial data from RAMP 205 trial of avutometinib/defactinib plus chemo in frontline metastatic pancreatic cancer expected H1 2024.","Data from RAMP 203 and RAMP 204 trials in KRAS G12C-mutant NSCLC planned for mid-2024.","Interim RAMP 201 results showed ORR 45% (13/29) and disease control 86% (25/29) in LGSOC; Phase 3 RAMP 301 initiated.","Collaborator GenFleet to advance oral KRAS G12D inhibitor GFH375/VS-7375 into Phase 1 in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243937,"accession_number":"0001558370-24-000375","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Verastem stockholders approve option exchange at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved one-time exchange of certain stock options held by executive officers, employees, and non-employee directors.","Vote: 8,197,712 for, 7,793,121 against, 25,382 abstentions; no broker non-votes.","Special meeting held January 17, 2024; 16,016,215 shares of 25,268,102 entitled were represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243936,"accession_number":"0001104659-24-002227","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Verastem extends Term C Loan draw deadline by one year to March 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended outside date for Term C Loan draw from March 31, 2024 to March 31, 2025.","Pays $150,000 amendment fee to lenders.","No other changes to loan terms; reaffirms representations and warranties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261350,"accession_number":"0001104659-23-112203","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Verastem appoints Daniel Calkins as permanent CFO; $300K salary + 25K stock option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Calkins appointed CFO effective Oct 24, 2023, after serving as interim since Oct 31, 2022.","Base salary $300,000, annual bonus target 35% of base, pro-rated for 2023.","Grant of 25,000 stock options at $6.89/share, vesting over 4 years with 1-year cliff.","Severance: 9 months salary (12 months upon Change of Control) plus COBRA subsidies.","Employment agreement replaces prior interim arrangement; standard non-compete/confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278592,"accession_number":"0001558370-23-016113","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.","ORR 58% in KRAS mutant LGSOC (7/12) vs 33% in KRAS wild-type (4/12).","Median duration of response 26.9 months; median PFS 20.0 months.","19% of patients (5/26) remained on treatment at data cutoff, minimum 17 months follow-up.","RAMP 201 Part A confirmed 45% ORR by independent review reported at ASCO 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278591,"accession_number":"0001558370-23-015656","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem posts corporate presentation; content not fully disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted on Verastem website on September 12, 2023, furnished as Exhibit 99.1.","Full content of presentation not included in provided filing text; only disclaimers visible.","No financial results, clinical data, or guidance changes specified in the filing.","Presentation likely covers pipeline and corporate strategy; investors should access company website.","Materiality of presentation is uncertain due to lack of substantive details in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278590,"accession_number":"0001104659-23-087888","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Verastem enters CEO employment agreement with Daniel Paterson; $600K salary, equity grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Paterson appointed President & CEO effective Aug 1, 2023; employment agreement signed Aug 2, 2023.","Base salary $600K/yr; annual bonus target 55% of base salary, pro-rated for 2023.","Granted option for 100,000 shares at $10.44/share; 50,000 time-based RSUs; 50,000 performance-based RSUs tied to FDA acceptance/approval of avutometinib+defactinib NDA.","Time-based awards vest 25% on 1-yr anniversary, then 6.25% quarterly over 4 yrs.","Severance: 12 months salary (18 months upon Change of Control), pro-rata bonus, COBRA, accelerated time-based vesting for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278589,"accession_number":"0001104659-23-080188","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.","President Dan Paterson appointed President and CEO effective August 1, 2023; also joins Board.","Paterson has 30+ years experience, led acquisition of avutometinib; company moving toward FDA approval in LGSOC.","Stuglik remains on Board and chairs new Commercialization Committee.","Committee members Kapur and Tollefson; annual retainers $10k, chair $20k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296800,"accession_number":"0001104659-23-073116","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Verastem raises ~$97.8M in underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 7,181,409 shares at $9.75, 1,538,591 pre-funded warrants at $9.749, and underwriters' option for 1,308,000 shares exercised in full.","Pre-funded warrants have $0.001 exercise price and 9.99% beneficial ownership limitation (waivable to 19.99%).","Closing expected June 21, 2023; proceeds for general corporate purposes (not specified)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296799,"accession_number":"0001104659-23-069473","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.","FDA Breakthrough Therapy for avutometinib + defactinib; accelerated approval filing planned.","Cash $111M as of Q1 2023; up to $150M credit facility; up to $95M milestones from Secura Bio.","Avutometinib shows best-in-class potential; expanding into NSCLC, pancreatic, CRC trials.","Confirmatory trial for LGSOC initiation expected in H2 2023; multiple readouts in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296798,"accession_number":"0001104659-23-066363","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Verastem effects 1-for-12 reverse stock split to meet Nasdaq price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective 5:00 p.m. ET May 31, 2023; trading on split-adjusted basis June 1 under VSTM.","Outstanding shares reduced from ~200,872,633 to ~16,739,386; CUSIP changed to 92337C203.","No fractional shares issued; cash paid at closing price of May 30 adjusted for 1-for-12 ratio.","Authorized shares remain 300,000,000; par value unchanged at $0.0001 per share.","Split designed to boost per-share price for continued Nasdaq listing and broader investor appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296797,"accession_number":"0001558370-23-010485","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.","KRAS mutant subgroup ORR 60% (9/15); KRAS wild type ORR 29% (4/14); median response time 5.5 months.","Safety profile consistent with prior data; discontinuation rate 12%, mostly due to elevated CPK (4.9%).","FDA Breakthrough Therapy Designation previously granted; company plans filing for accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296796,"accession_number":"0001558370-23-010004","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Verastem shareholders approve reverse stock split ratio 1:10-30, elect three Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Robert Gagnon, Brian Stuglik, and Karin Tollefson as Class II directors until 2026 annual meeting.","Approved reverse stock split (1:10-30) with Board discretion until 12/31/2023; 113.9M for, 21.4M against.","Ratified Ernst & Young as independent auditor for fiscal year; 133.0M for, 2.2M against.","Advisory vote approved compensation of named executive officers; 61.3M for, 24.5M against, 49.2M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317181,"accession_number":"0001104659-23-037143","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Verastem draws $15M Term B Loan from Oxford Finance facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $15M Term B Loan on March 22, 2023, after receiving at least $50M in equity proceeds.","Loan carries floating rate of SOFR (floor 0.13%) + 7.37%; interest payable monthly.","Repayment begins April 1, 2025; maturity March 1, 2027; final payment of 5% of original principal.","Prepayment fees range from 1% to 3% depending on timing; no financial covenants.","Total facility up to $150M; previous draw $25M, now total drawn $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317180,"accession_number":"0001104659-23-031411","cik":1526119,"company_name":"Verastem, Inc.","ticker":"VSTM","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Verastem reports $2M deposit at Silicon Valley Bank; depositors fully protected by FDIC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company had ~$2 million on deposit at SVB when FDIC took control.","Treasury, Fed, and FDIC announced all SVB depositors will be fully protected starting March 13, 2023.","Verastem expects full access to its cash without loss.","No other material exposure to SVB disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":364680000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}